Skip to content

Genenta Science S.p.A.: 20-F filed 2024-03-29

What Genenta Science S.p.A. reported in its annual report (foreign private issuer) filed 2024-03-29 (fiscal FY 2023): 34 published measures, 97 facts as tagged in accession 0001493152-24-011999.

This filing

Form
20-F (annual report (foreign private issuer))
Filed
2024-03-29
Fiscal period
fiscal FY 2023
Accession
0001493152-24-011999 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Genenta Science S.p.A. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-12-3122,347,145EUR
At 2022-12-3133,437,860EUR
At 2021-12-3140,026,840EUR

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-12-3120,432,257EUR
At 2022-12-3131,138,166EUR
At 2021-12-3138,861,183EUR
At 2020-12-3115,151,309EUR

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-12-313,691,420EUR
At 2022-12-3129,794,856EUR
At 2021-12-3137,240,162EUR

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-11,645,455EUR365
2022-01-01 to 2022-12-31-8,477,763EUR365
2021-01-01 to 2021-12-31-5,529,332EUR365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-11,205,023EUR365
2022-01-01 to 2022-12-31-7,418,236EUR365
2021-01-01 to 2021-12-31-6,958,174EUR365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2023-01-01 to 2023-12-3113,791EUR365
2022-01-01 to 2022-12-3127,070EUR365
2021-01-01 to 2021-12-319,009EUR365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-12-31531EUR365
2021-01-01 to 2021-12-3128,742,102EUR365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-14,892,666EUR365
2022-01-01 to 2022-12-31-27,070EUR365
2021-01-01 to 2021-12-31-9,009EUR365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-12-31-47,143,025EUR
At 2022-12-31-35,465,559EUR
At 2021-12-31-27,019,807EUR

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-01-01 to 2023-12-3118,216,907shares365
2022-01-01 to 2022-12-3118,216,858shares365
2021-01-01 to 2021-12-3115,083,825shares365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-01-01 to 2023-12-3118,216,907shares365
2022-01-01 to 2022-12-3118,216,858shares365
2021-01-01 to 2021-12-3115,083,825shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-0.64EUR/shares365
2022-01-01 to 2022-12-31-0.47EUR/shares365
2021-01-01 to 2021-12-31-0.37EUR/shares365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-0.64EUR/shares365
2022-01-01 to 2022-12-31-0.47EUR/shares365
2021-01-01 to 2021-12-31-0.37EUR/shares365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-12-3182,977EUR
At 2022-12-31111,639EUR
At 2021-12-3123,090EUR

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-12-31739,884EUR365
2022-01-01 to 2022-12-31722,735EUR365
2021-01-01 to 2021-12-31497,104EUR365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-11,732,942EUR365
2022-01-01 to 2022-12-31-11,043,992EUR365
2021-01-01 to 2021-12-31-5,687,273EUR365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-12-3121,256,258EUR
At 2022-12-3131,721,368EUR
At 2021-12-3138,759,185EUR

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-12-311,735,639EUR
At 2022-12-312,183,513EUR
At 2021-12-311,135,039EUR

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-01-01 to 2023-12-3111,732,942EUR365
2022-01-01 to 2022-12-3111,043,992EUR365
2021-01-01 to 2021-12-315,687,273EUR365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-01-01 to 2023-12-316,474,441EUR365
2022-01-01 to 2022-12-315,338,962EUR365
2021-01-01 to 2021-12-313,390,677EUR365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-12-3118,216,958shares
At 2022-12-3118,216,858shares
At 2021-12-3118,216,858shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2021-05-2037,139,431EUR

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2023-12-31231,142EUR

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2023-12-31136,776EUR
At 2022-12-31123,783EUR
At 2021-12-3129,879EUR

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-12-3153,799EUR
At 2022-12-3112,144EUR
At 2021-12-316,789EUR

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-12-3114,594EUR
At 2022-12-3127,218EUR

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2023-12-312,480,554EUR
At 2022-12-311,926,512EUR
At 2021-12-311,519,023EUR

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-11,645,455EUR365
2022-01-01 to 2022-12-31-8,477,763EUR365
2021-01-01 to 2021-12-31-5,529,332EUR365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-11,446,324EUR365
2022-01-01 to 2022-12-31-8,477,763EUR365
2021-01-01 to 2021-12-31-5,529,332EUR365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-01-01 to 2023-12-315,258,501EUR365
2022-01-01 to 2022-12-315,705,030EUR365
2021-01-01 to 2021-12-312,296,596EUR365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2023-01-01 to 2023-12-3142,453EUR365
2022-01-01 to 2022-12-316,140EUR365
2021-01-01 to 2021-12-314,889EUR365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-4,875EUR365
2022-01-01 to 2022-12-31242,554EUR365
2021-01-01 to 2021-12-3119,657EUR365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-01-01 to 2023-12-3187,487EUR365
2022-01-01 to 2022-12-312,566,229EUR365
2021-01-01 to 2021-12-31157,941EUR365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-747,079EUR365
2022-01-01 to 2022-12-31877,235EUR365
2021-01-01 to 2021-12-31-380,169EUR365

Inspect the source

Entity
Genenta Science S.p.A. / CIK 0001838716
Captured
2026-09-21T17:29:52.350Z
SEC response SHA-256
ede626b2bf4430180410f5478c106929c7cdb4ab42ea2438ebd16270765025a5

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001838716.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))